MetaCap

Galectin Therapeutics (GALT) vs Q32 Bio (QTTB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Q32 Bio (QTTB) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 317.0% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -91.1% for QTTB. Galectin Therapeutics is the larger company by market cap ($271.4 million vs $249.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GALT-49.72%QTTB+317.00%
+1021%+454%-113%
Nov 21, 20251 yearNov 20, 2026
GALT0.00%QTTB-91.04%
+144%+17%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GALT versus QTTB key metrics
MetricGALTQTTB
Share price$2.69$8.34
Market cap$271.35M$249.57M
1-day change-4.27%-1.65%
YTD return-35.34%+151.20%
1-year return-49.72%+317.00%
5-year return+4.67%-91.12%
P/E ratio (TTM)—2.32
EPS (TTM)$-0.32$3.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$53.74M
Net income (latest FY)$-30.84M$29.82M
Operating margin—31.45%
Net margin—55.49%
52-week high$7.13$23.57
52-week low$2.03$1.98
Distance from 52-week high-62.27%-64.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+308.92%+375.66%
Average volume252.31K692.58K
Shares outstanding100.88M29.92M
Employees925
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QTTB has outperformed GALT by 366.7 percentage points over the past year.

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Q32 Bio

QTTB stock →

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

GALT vs QTTB FAQ

Which is bigger, Galectin Therapeutics or Q32 Bio?

Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $249.57M for Q32 Bio (QTTB).

Which stock has performed better over the past year, GALT or QTTB?

QTTB returned +317.00% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.

Are Galectin Therapeutics and Q32 Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons